MCID: SCH012
MIFTS: 51

Schizoaffective Disorder

Categories: Mental diseases

Aliases & Classifications for Schizoaffective Disorder

MalaCards integrated aliases for Schizoaffective Disorder:

Name: Schizoaffective Disorder 12 72 51 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5418
ICD10 32 F25 F25.9
ICD9CM 34 295.7
MeSH 41 D011618
NCIt 46 C94378
UMLS 69 C0036337

Summaries for Schizoaffective Disorder

Disease Ontology : 12 A psychotic disorder that is characterized by recurring episodes of mood fluctuations and a loss of contact with reality.

MalaCards based summary : Schizoaffective Disorder is related to schizophreniform disorder and hyperprolinemia. An important gene associated with Schizoaffective Disorder is DISC1 (Disrupted In Schizophrenia 1), and among its related pathways/superpathways are Neuroscience and Monoamine GPCRs. The drugs Dopamine and Simvastatin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 72 Schizoaffective disorder (SZA, SZD or SAD) is a mental disorder characterized by abnormal thought... more...

Related Diseases for Schizoaffective Disorder

Diseases related to Schizoaffective Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 125, show less)
# Related Disease Score Top Affiliating Genes
1 schizophreniform disorder 30.5 COMT DRD2 PRL
2 hyperprolinemia 30.2 COMT PRODH
3 delusional disorder 30.1 DRD2 DRD3
4 tardive dyskinesia 30.0 COMT DRD2 DRD3 HTR2A
5 anxiety 29.9 BDNF COMT HTR2A SLC6A4
6 cocaine dependence 29.9 DRD2 DRD3 SLC6A4
7 paranoid schizophrenia 29.7 BDNF COMT HTR2A SLC6A4
8 schizotypal personality disorder 29.7 COMT SULT4A1
9 pathological gambling 29.6 DRD2 DRD3 HTR2A SLC6A4
10 bipolar i disorder 29.6 BDNF COMT DTNBP1 HTR2A SLC6A4
11 borderline personality disorder 29.5 BDNF COMT HTR2A SLC6A4
12 mood disorder 29.3 BDNF COMT DAOA DISC1 DRD2 HTR2A
13 personality disorder 29.2 BDNF COMT DRD2 DRD3 HTR2A SLC6A4
14 substance abuse 29.0 BDNF COMT DRD2 DRD3 PRL SLC6A4
15 early-onset schizophrenia 29.0 BDNF COMT DRD2 DRD3 HTR2A SLC6A4
16 obsessive-compulsive disorder 28.8 BDNF COMT DRD2 DRD3 HTR2A PRL
17 bipolar disorder 28.5 BDNF COMT DAOA DISC1 DRD2 DRD3
18 major depressive disorder 28.5 BDNF COMT DISC1 DRD2 DRD3 HTR2A
19 alcohol dependence 28.4 BDNF COMT DRD2 DRD3 GABRB1 HTR2A
20 schizophrenia 27.2 BDNF CHRFAM7A COMT DAOA DISC1 DRD2
21 psychotic disorder 27.0 BDNF COMT DAOA DISC1 DRD2 DRD3
22 schizophrenia 4 10.8
23 schizophrenia 2 10.8
24 schizophrenia 9 10.8
25 schizophrenia 15 10.8
26 chromosome 2p16.3 deletion syndrome 10.8
27 schizophrenia 18 10.8
28 schizophrenia 19 10.8
29 galactorrhea 10.4 DRD2 PRL
30 obsessive-compulsive personality disorder 10.4 DRD3 SLC6A4
31 alzheimer disease 5 10.3 HTR2A SLC6A4
32 alcohol use disorder 10.3 DRD2 SLC6A4
33 prolactin producing pituitary tumor 10.3 DRD2 PRL
34 polysubstance abuse 10.3 COMT DRD2 DRD3
35 impulse control disorder 10.3 DRD2 DRD3
36 alcohol-induced mental disorder 10.3 DRD2 SLC6A4
37 social phobia 10.2 DRD2 PRL SLC6A4
38 opiate dependence 10.2 DRD2 DRD3 SLC6A4
39 mammographic density 10.2 COMT PRL
40 oppositional defiant disorder 10.2 COMT DRD2 SLC6A4
41 alexithymia 10.2 COMT DRD2 SLC6A4
42 restless legs syndrome 10.2 COMT DRD2 DRD3
43 psychosexual disorder 10.2 HTR2A SLC6A4
44 childhood-onset schizophrenia 10.2 COMT DAOA PRL PRODH
45 cocaine abuse 10.2 DRD2 PRL SLC6A4
46 antisocial personality disorder 10.2 COMT DRD2 SLC6A4
47 traumatic brain injury 10.2 BDNF COMT DRD2
48 alcoholic psychosis 10.2 DRD2 HTR2A SLC6A4
49 conduct disorder 10.2 COMT DRD2 SLC6A4
50 periodic limb movement disorder 10.2 DRD2 HTR2A SLC6A4
51 bruxism 10.2 DRD2 HTR2A SLC6A4
52 brain injury 10.2 BDNF COMT DRD2
53 tobacco addiction 10.2 COMT DRD2 HTR2A
54 gilles de la tourette syndrome 10.1 BDNF COMT DRD2
55 specific developmental disorder 10.1 BDNF COMT SLC6A4
56 migraine without aura 10.1 DRD2 DRD3 PRL SLC6A4
57 body mass index quantitative trait locus 11 10.1
58 aging 10.1
59 body mass index quantitative trait locus 9 10.1
60 body mass index quantitative trait locus 8 10.1
61 body mass index quantitative trait locus 7 10.1
62 body mass index quantitative trait locus 12 10.1
63 body mass index quantitative trait locus 14 10.1
64 body mass index quantitative trait locus 18 10.1
65 endogenous depression 10.1 BDNF HTR2A SLC6A4
66 phobic disorder 10.1 COMT SLC6A4
67 body mass index quantitative trait locus 4 10.1
68 body mass index quantitative trait locus 10 10.1
69 postpartum depression 10.0 BDNF COMT PRL SLC6A4
70 drug dependence 10.0 BDNF DRD2 DRD3 SLC6A4
71 substance dependence 10.0 BDNF DRD2 DRD3 SLC6A4
72 eating disorder 10.0 BDNF COMT DRD2 SLC6A4
73 mental depression 10.0 BDNF COMT HTR2A SLC6A4
74 bulimia nervosa 1 10.0 BDNF COMT HTR2A SLC6A4
75 multiple sclerosis 9.9
76 mungan syndrome 9.9
77 panic disorder 9.9 BDNF COMT HTR2A SLC6A4
78 generalized anxiety disorder 9.9 BDNF DRD2 HTR2A SLC6A4
79 dysthymic disorder 9.9 HTR2A SLC6A4
80 central nervous system disease 9.9 BDNF HTR2A SLC6A4
81 schizophrenia 1 9.9
82 pituitary adenoma, prolactin-secreting 9.9
83 hepatitis 9.9
84 dementia 9.9
85 alcohol abuse 9.8 BDNF DRD2 DRD3 PRL SLC6A4
86 intermittent explosive disorder 9.8 CHRFAM7A PRL SLC6A4
87 bulimia nervosa 2 9.8 BDNF COMT HTR2A PRL SLC6A4
88 post-traumatic stress disorder 9.7 BDNF COMT DRD2 HTR2A SLC6A4
89 arteries, anomalies of 9.7
90 blood group, i system 9.7
91 major affective disorder 1 9.7
92 cognitive function 1, social 9.7
93 major affective disorder 2 9.7
94 basal cell carcinoma 1 9.7
95 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.7
96 major affective disorder 4 9.7
97 major affective disorder 5 9.7
98 major affective disorder 6 9.7
99 major affective disorder 8 9.7
100 major affective disorder 7 9.7
101 major affective disorder 9 9.7
102 coronary artery anomaly 9.7
103 diabetes mellitus 9.7
104 hepatitis b 9.7
105 neutropenia 9.7
106 thrombocytopenia 9.7
107 allergic hypersensitivity disease 9.7
108 porphyria 9.7
109 basal cell carcinoma 9.7
110 acute porphyria 9.7
111 cerebritis 9.7
112 myopathy 9.7
113 neuronitis 9.7
114 myocarditis 9.7
115 encephalopathy 9.7
116 headache 9.7
117 hypoxia 9.7
118 ring chromosome y syndrome 9.7
119 argyria 9.7
120 parkinson disease, late-onset 9.6 BDNF COMT DRD2 DRD3 HTR2A SLC6A4
121 migraine with or without aura 1 9.5 COMT DRD2 DRD3 HTR2A NOTCH4 SLC6A4
122 autism spectrum disorder 9.4 BDNF COMT DISC1 DRD2 DRD3 HTR2A
123 autism 9.4 BDNF COMT DISC1 DRD2 DRD3 HTR2A
124 disease of mental health 9.1 BDNF COMT DISC1 DRD2 DRD3 DTNBP1
125 attention deficit-hyperactivity disorder 9.0 BDNF CHRFAM7A COMT DRD2 DRD3 HTR2A

Graphical network of the top 20 diseases related to Schizoaffective Disorder:



Diseases related to Schizoaffective Disorder

Symptoms & Phenotypes for Schizoaffective Disorder

MGI Mouse Phenotypes related to Schizoaffective Disorder:

43 (showing 3, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.93 BDNF COMT DISC1 DRD2 DRD3 DTNBP1
2 homeostasis/metabolism MP:0005376 9.73 PRL PRODH SLC1A1 SLC6A4 BDNF COMT
3 nervous system MP:0003631 9.44 DRD3 DTNBP1 GABRB1 NOTCH4 PRL PRODH

Drugs & Therapeutics for Schizoaffective Disorder

Drugs for Schizoaffective Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 378, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
2
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
3
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
4
Donepezil Approved Phase 4 120014-06-4 3152
5
Haloperidol Approved Phase 4,Phase 3 52-86-8 3559
6
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
7
Clozapine Approved Phase 4,Phase 1 5786-21-0 2818
8
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
9
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
10
Ziprasidone Approved Phase 4,Phase 2,Phase 3 146939-27-7 60854
11
Citalopram Approved Phase 4 59729-33-8 2771
12
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 1 10118-90-8 5281021
13
Pimozide Approved Phase 4 2062-78-4 16362
14
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
15
Sulpiride Approved, Investigational Phase 4 15676-16-1 5355
16
Perphenazine Approved Phase 4 58-39-9 4748
17
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
18
Fluphenazine Approved Phase 4 69-23-8 3372
19 Benperidol Approved, Investigational Phase 4 2062-84-2
20 bromperidol Approved, Investigational Phase 4 10457-90-6
21
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 1 68693-11-8 4236
22
Armodafinil Approved, Investigational Phase 4,Phase 2,Phase 1 112111-43-0
23 Perazine Approved, Investigational Phase 4 84-97-9
24
Ethanol Approved Phase 4,Phase 1,Phase 2 64-17-5 702
25
Norepinephrine Approved Phase 4 51-41-2 439260
26
Cocaine Approved, Illicit Phase 4,Phase 3 50-36-2 446220 5760
27
Nicotine Approved Phase 4,Phase 2,Phase 3 54-11-5 89594 942
28
Pravastatin Approved Phase 4 81093-37-0 54687
29
Zinc Approved, Investigational Phase 4 7440-66-6 32051 23994
30
Metformin Approved Phase 4,Phase 3 657-24-9 4091 14219
31
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 1 99-66-1 3121
32
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
33
Galantamine Approved Phase 4,Phase 3,Phase 2 357-70-0 9651
34
Acetylcholine Approved Phase 4,Phase 2 51-84-3 187
35
Allopurinol Approved Phase 4 315-30-0 2094
36
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
37
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2 300-62-9 3007 5826
38
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
39
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
40
Pramlintide Approved, Investigational Phase 4 151126-32-8
41
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
42
Amantadine Approved Phase 4,Phase 3,Phase 1 768-94-5 2130
43
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
44
Lorazepam Approved Phase 4,Phase 3,Phase 2 846-49-1 3958
45
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2 249296-44-4 5310966
46
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
47
Asenapine Approved Phase 4,Phase 3,Phase 2 85650-56-2, 65576-45-6 3001386
48
Molindone Approved Phase 4 7416-34-4 23897
49
Cycloserine Approved Phase 4,Phase 2,Phase 3 68-41-7 6234 401
50
Losartan Approved Phase 4 114798-26-4 3961
51
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
52
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
53
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
54
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
55
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
56
Glutamic Acid Approved, Nutraceutical Phase 4 56-86-0 33032
57
Betadex Experimental Phase 4 7585-39-9 320761
58 valacyclovir Phase 4,Phase 2
59 Haloperidol decanoate Phase 4,Phase 3
60 sultopride Phase 4
61 Quetiapine Fumarate Phase 4,Phase 2,Phase 3,Phase 1 111974-72-2
62 Lithium carbonate Phase 4,Phase 2,Phase 1 554-13-2
63
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
64 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
65 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
66 Fluphenazine depot Phase 4
67 Fluphenazine enanthate Phase 4
68 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
69 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2
70 Central Nervous System Stimulants Phase 4,Phase 2,Phase 1
71 Adrenergic Agonists Phase 4
72 Serotonin 5-HT2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
73 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
74 Adrenergic alpha-2 Receptor Agonists Phase 4
75 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1
76 Adrenergic alpha-Agonists Phase 4
77 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
78 Muscarinic Antagonists Phase 4
79 N-Methylaspartate Phase 4,Phase 2
80 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
81 GABA Agents Phase 4,Phase 3,Phase 2,Phase 1
82 Cholinergic Antagonists Phase 4
83 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 2
84 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
85 Clopenthixol Phase 4
86 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
87 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
88 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2
89 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
90 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1,Phase 2
91 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 2,Phase 1
92 Nootropic Agents Phase 4,Phase 3,Phase 2
93 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
94 Paliperidone Palmitate Phase 4,Phase 3,Phase 2,Phase 1
95 Hormones Phase 4,Phase 3,Phase 2,Phase 1
96 Parasympatholytics Phase 4
97 Wakefulness-Promoting Agents Phase 4,Phase 2,Phase 1
98 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
99 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
100 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
101 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
102 Dopamine D2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
103 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
104 Anticholesteremic Agents Phase 4,Phase 3,Phase 2,Phase 1
105 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
106 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1
107 Antidepressive Agents, Second-Generation Phase 4
108 Hypolipidemic Agents Phase 4,Phase 3,Phase 2,Phase 1
109 Estrogen Antagonists Phase 4,Phase 3,Phase 2
110 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
111 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2
112 Estrogens Phase 4,Phase 3,Phase 2
113 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
114 Immunoglobulins Phase 4,Phase 1,Phase 2
115 Antihypertensive Agents Phase 4
116 Antimanic Agents Phase 4,Phase 2,Phase 1
117 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
118 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
119 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 1,Phase 2
120 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
121 Lipid Regulating Agents Phase 4,Phase 3,Phase 2,Phase 1
122 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
123 Antibodies Phase 4,Phase 1,Phase 2
124 Raloxifene Hydrochloride Phase 4,Phase 3,Phase 2
125 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
126 Antioxidants Phase 4,Phase 3,Phase 2
127 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
128 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1
129 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2
130 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
131 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
132 decanoic acid Phase 4,Phase 3
133 Acyclovir Phase 4
134 insulin Phase 4,Phase 1,Phase 2
135
Benztropine Phase 4 86-13-5 6832
136 Sodium salicylate Phase 4 54-21-7
137 Renal Agents Phase 4,Phase 2,Phase 3
138 Retinol palmitate Phase 4
139 Salicylates Phase 4
140 Salicylsalicylic acid Phase 4
141 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
142 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2,Phase 1
143 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
144 Narcotic Antagonists Phase 4,Phase 2
145 Narcotics Phase 4,Phase 2
146 GABA Modulators Phase 4,Phase 3,Phase 2,Phase 1
147 Neuroprotective Agents Phase 4,Phase 2,Phase 1
148 Nicotinic Agonists Phase 4,Phase 3,Phase 2
149 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
150 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2
151 Cytochrome P-450 Enzyme Inhibitors Phase 4
152 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
153 Anesthetics, Local Phase 4,Phase 3
154 Angiotensin II Type 1 Receptor Blockers Phase 4
155 Angiotensin Receptor Antagonists Phase 4
156 Angiotensinogen Phase 4
157 Anti-Arrhythmia Agents Phase 4,Phase 1
158 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2
159 Duloxetine Hydrochloride Phase 4
160 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
161 Hypoglycemic Agents Phase 4,Phase 3,Phase 2
162 Pharmaceutical Solutions Phase 4,Phase 2
163 Antifungal Agents Phase 4
164 Anti-Infective Agents, Local Phase 4
165 Incretins Phase 4,Phase 2
166 Insulin, Globin Zinc Phase 4,Phase 1,Phase 2
167 Anti-Obesity Agents Phase 4,Phase 1
168 Islet Amyloid Polypeptide Phase 4
169 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3
170 Liver Extracts Phase 4
171 Antineoplastic Agents, Hormonal Phase 4,Phase 2
172
Lurasidone hydrochloride Phase 4,Phase 3,Phase 2,Phase 1 367514-87-2 213046
173 Appetite Depressants Phase 4
174 Atomoxetine Hydrochloride Phase 4
175 Antitubercular Agents Phase 4,Phase 2,Phase 3
176 Prednisolone acetate Phase 4
177 glucocorticoids Phase 4
178 Methylprednisolone acetate Phase 4
179 Methylprednisolone Hemisuccinate Phase 4
180 Prednisolone hemisuccinate Phase 4
181 Prednisolone phosphate Phase 4
182 Respiratory System Agents Phase 4
183 N-monoacetylcystine Phase 4
184 Antidotes Phase 4
185 Expectorants Phase 4
186 Aspartic Acid Nutraceutical Phase 4,Phase 2
187 retinol Nutraceutical Phase 4
188 Omega 3 Fatty Acid Nutraceutical Phase 4,Phase 2,Phase 3
189 cysteine Nutraceutical Phase 4
190
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
191
Pramipexole Approved, Investigational Phase 3 104632-26-0 119570 59868
192
Buspirone Approved, Investigational Phase 3 36505-84-7 2477
193
Zonisamide Approved, Investigational Phase 3,Phase 2 68291-97-4 5734
194
Hydroxocobalamin Approved Phase 3 13422-51-0 5460373 44475014 11953898
195
Tetrabenazine Approved, Investigational Phase 3,Phase 2 58-46-8 6018
196
Carbon monoxide Approved, Investigational Phase 2, Phase 3 630-08-0 281
197
Mifepristone Approved, Investigational Phase 2, Phase 3 84371-65-3 55245
198
Glycine Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 56-40-6 750
199
Niacin Approved, Investigational, Nutraceutical Phase 2, Phase 3 59-67-6 938
200
Choline Approved, Nutraceutical Phase 3,Phase 2 62-49-7 305
201
Vitamin C Approved, Nutraceutical Phase 2, Phase 3 50-81-7 54670067 5785
202
Nicotinamide Approved, Investigational, Nutraceutical Phase 2, Phase 3 98-92-0 936